Ads
related to: breast cancer treatment drugs herceptin prescribed- Tips On Living With mBC
Tips On Coping, Motherhood,
Relationships & Nutrition
- Metastatic Breast Cancer
Visit For Info On A Metastatic
Breast Cancer Rx Treatment Option.
- mBC Patient Stories
Find Inspirational Stories Of Women
With Metastatic Breast Cancer
- Doctor Discussion Guide
Find A Discussion Guide To Aid
In Talking With Your Doctor
- Tips On Living With mBC
Search results
Results From The WOW.Com Content Network
Clinical trial number NCT01566721 for "A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)" at ClinicalTrials.gov
Trastuzumab. Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [20] [17] [21] [22] It is specifically used for cancer that is HER2 receptor positive. [20] It may be used by itself or together with other chemotherapy medication. [20]
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan ). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...
In the United States, trastuzumab emtansine was approved specifically for treatment of HER2-positive metastatic breast cancer (mBC) in patients who have been treated previously with trastuzumab and a taxane (paclitaxel or docetaxel), and who have already been treated for mBC or developed tumor recurrence within six months of adjuvant therapy.
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and safety as IV ...
Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonist/antagonists (ERAAs), [1] [2] is a class of drugs that act on estrogen receptors (ER). [3] A characteristic that distinguishes these substances from pure ER agonists-antagonists (ex., full agonists and silent antagonists) is that their action is different in various tissues, allowing them to selectively ...
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Ads
related to: breast cancer treatment drugs herceptin prescribed